Home | Screening data | Screen comparisons | Search for compounds | Structure search

Compound InformationSONAR Target prediction
Name:

PAPAVERINE HYDROCHLORIDE

Unique Identifier:SPE01500459
MolClass: Checkout models in ver1.5 and ver1.0
Molecular Formula:
Molecular Weight:353.671 g/mol
X log p:15.917  (online calculus)
Lipinksi Failures1
TPSA49.28
Hydrogen Bond Donor Count:0
Hydrogen Bond Acceptors Count:5
Rotatable Bond Count:6
Canonical Smiles:Cl.COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
Class:alkaloid
Source:Papaver somniferum, Rauwolfia serpentina
Therapeutics:muscle relaxant (smooth), cerebral vasodilator
Generic_name:Papaverine
Chemical_iupac_name:1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline
Drug_type:Approved Drug
Pharmgkb_id:PA450779
Drugbank_id:APRD00628
Logp:3.72
Cas_registry_number:61-25-6
Drug_category:Vasodilator Agents; ATC:A03AD01; ATC:G04BE02
Indication:Impotence
Pharmacology:Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral
and peripheral ischemia associated with arterial spasm and myocardial ischemia
complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac
and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to
depress conduction and prolong the refractory period. Papaverine relaxes various
smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is
not paralyzed by Papaverine and still responds to drugs and other stimuli causing
contraction. The antispasmodic effect is a direct one, and unrelated to muscle
innervation. Papaverine is practically devoid of effects on the central nervous
system. Papaverine relaxes the smooth musculature of the larger blood vessels,
especially coronary, systemic peripheral, and pulmonary arteries.
Mechanism_of_action:Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine
increases cerebral blood flow and decreases cerebral vascular resistance in normal
subjects; oxygen consumption is unaltered. These effects may explain the benefit
reported from the drug in cerebral vascular encephalopathy.
Organisms_affected:Humans and other mammals

Found: 205 nonactive as graph: single | with analogs [1] << Back 11 12 13 14 15 16 17 18 19 20  Next >> [205]
Species: 4932
Condition: ARP1
Replicates: 2
Raw OD Value: r im 0.7342±0.00311127
Normalized OD Score: sc h 1.0212±0.00616358
Z-Score: 1.0575±0.229192
p-Value: 0.296614
Z-Factor: -1.69513
Fitness Defect: 1.2153
Bioactivity Statement: Nonactive
Experimental Conditions
Library:Spectrum
Plate Number and Position:16|F5
Drug Concentration:50.00 nM
OD Absorbance:600 nm
Robot Temperature:27.20 Celcius
Date:2006-03-23 YYYY-MM-DD
Plate CH Control (+):0.040874999999999995±0.00138
Plate DMSO Control (-):0.710225±0.01071
Plate Z-Factor:0.9412
png
ps
pdf

DBLink | Rows returned: 92 Next >> 
4680 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline
6084 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline hydrochloride
100248 4-[(6,7-dimethoxyisoquinolin-1-yl)methyl]-2-methoxy-phenol
425899 3-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline
426677 1-[(3,4-dimethoxyphenyl)methyl]-5,6-dimethoxy-isoquinoline
657373 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline; hydrogen(+1) cation; chloride

internal high similarity DBLink | Rows returned: 3
SPE01501000 0.9057
LOPAC 00582 1.0000
SB 01383 1.0000

nonactive | Cluster 1145 | Additional Members: 7 | Rows returned: 4
SPE01501000 0.4
Prest1049 0.4
LOPAC 00582 0
Prest376 0

Service provided by the Mike Tyers Laboratory